A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity
Open Access
- 1 January 1992
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 2 (1) , 35-40
- https://doi.org/10.1046/j.1525-1438.1992.02010035.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancerGynecologic Oncology, 1990
- First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancerBritish Journal of Cancer, 1989
- A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.Journal of Clinical Oncology, 1989
- Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.Journal of Clinical Oncology, 1987
- Phase II trial of VP-16-213 in advanced ovarian carcinomaGynecologic Oncology, 1985
- Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial.Journal of Clinical Oncology, 1985
- Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumorsThe American Journal of Medicine, 1985
- Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdensCancer, 1983